Article

Visfatin and gallstone disease.

Department of Gastroenterology, Gulhane School of Medicine, Etlik, Ankara-Turkey.
American journal of surgery (Impact Factor: 2.36). 03/2012; 203(3):410. DOI: 10.1016/j.amjsurg.2009.06.022
Source: PubMed
0 Bookmarks
 · 
111 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Visfatin with the official gene name pre-B cell colony-enhancing factor 1 (PBEF) and the protein name nicotinamide phosphoribosyltransferase (NAMPT) is a recently discovered adipocyte-secreted protein that was shown by some to be associated with visceral fat and insulin resistance. To explore the link between PBEF/NAMPT/visfatin and lipid metabolism, we analyzed the relation of its plasma level with several parameters of adiposity, insulin resistance and the circulating blood lipid profile in a group of general population (n = 40) and a group of subjects who are genetically predisposed to insulin resistance and hyperlipidemia (n = 35). In both groups and pooled cohort, PBEF/NAMPT/visfatin lacked association with whole body adiposity, but correlated positively with HDL-cholesterol and negatively with triglycerides. The data suggested a negative correlation of the PBEF level with visceral fat and insulin resistance. But this negative correlation completely disappeared after adjustment for lipid profile. We concluded that circulating PBEF/NAMPT/visfatin level is an indicator of beneficial lipid profile in non-diabetic Caucasian subjects. The relation to lipid metabolism does not depend on visceral obesity and insulin resistance, but may be linked to its enzymatic function in NAD metabolism.
    Pflügers Archiv - European Journal of Physiology 10/2007; 454(6):971-6. · 4.87 Impact Factor